


# **Cancer Incidence Among Atomic Bomb Survivors: Second Follow-up**



# Outline


- Life Span Study (LSS) cancer incidence cohort
- Cancer incidence follow-up 1958-1995
- Major results
  - All solid cancers
  - Site-specific risks
- Summary remarks

# Objectives of Incidence Report

- Quantify cancer risks attributable to radiation
- Explore the shape of the dose-response
- Assess how the risk is modified by age, time, gender and other factors
- Seek insights into site-specific differences in risk patterns

# **LSS Cancer Incidence Cohort**

- **Survivors within 2.5 km of the bombings**
- **Survivors within 2.5 -10 km**
- **Not-in-city (NIC)**
- **Known DS02 dose**
- **Alive and cancer free in 1958**





Preliminary data – not for distribution

# Strengths of LSS Incidence Cohort

- Large study population
- Basically healthy non-selected population
- All ages and both sexes
- Well characterized dose estimates
- Wide range of doses
- Complete ascertainment in tumor registry catchment areas
- More than 50 years of follow-up

# Projections: Aging of Younger Cohorts



Preliminary data – not for distribution

# Updated Cancer Incidence Report

- 1958-1998
- 105,384 people
- 44% alive in 2000
  - ~85% of those <20 at the time of the bombings
- First primary tumors
- DS02 organ dose estimates



# LSS Cohorts

	Incidence	Mortality
Yr. follow-up began	1958	1950
Study population*	80,139	86,572
Mean age at bomb	26.8	29.0
Endpoint	Cancer only	All deaths
Ascertainment	Cancer registries	Family registry
Catchment area	Hiroshima and Nagasaki	All Japan

\* *Excluding NIC*

Preliminary data – not for distribution

# Strengths of LSS Cancer Incidence Data

- Data on non-fatal cancers
- High level cancer ascertainment
- Accurate diagnoses
- Information on histology
- Includes some benign tumors
- Long follow-up

# LSS Tumor Registry

**Hiroshima & Nagasaki catchment area**

**Active case ascertainment**

- *Large hospitals*
- *Tissue registries*
- *Death certificates*
- *Medical associations (small hospitals)*

**No dose bias in case ascertainment**

# **Limitations of LSS Cancer Incidence Data**

- **No solid cancer data from 1945-1958**
- **No leukemia data from 1945-1950**
- **Cancer data limited to Hiroshima and Nagasaki area residents**
- **Limited treatment data**

# LSS COHORT

Dose, Sv	Subjects	(%)
< 0.005	34,582	43.2
0.005 - 0.1	29,352	36.6
0.1 - 0.2	5,316	6.6
0.2 - 0.5	5,897	7.4
0.5 - 1	3,057	3.8
1 - 2	1,503	1.9
2+	436	0.5

Preliminary data – not for distribution

# Magnitude of Doses

**A-bomb survivors: Average dose ~ 0.25 Sv**

**Nuclear workers: Average dose ~0.004 Sv/yr**

**Environmental exposure: Doses < 0.001 Sv**

**Diagnostic medical exposures: 0.001-0.01 Sv\***

**Therapeutic medical exposures: Can be  
as high as 80 Sv**

*\* Lower doses for x-rays higher for CT*

**Preliminary data – not for distribution**

# **Statistical Methods**

**DS86 total kerma ( $>4 \text{ Gy} = 4 \text{ Gy}$ )**

**Tumor registry catchment area**

**Migration adjustment of person years**

**General excess relative (ERR) and  
absolute (EAR) risk models**

**Linear dose-response standard model**

**Modifying effects of gender and age**

# LSS Cancer Incidence Data

Period	Person Years*	Cases
1958-1995^	1,989,123	12,161
1958 – 1987	1,655,000	8,613

*\*Adjusted for migration from catchment area*

*^ Does not includes NIC*

Preliminary data – not for distribution



# Distribution of Solid Cancers

Site	1958-87	1958-95
Digestive system	4,797	6,893
Respiratory system	1,027	1,413
Female genital	891	1,062
Breast	529	777
Urinary system	325	501
Thyroid	225	384
Skin	181	260
Male genital	160	266
Oral cavity	132	180
Nervous system	125	183

Preliminary data – not for distribution


# Solid Cancers: 1958 - 1995

<u>Dose, Sv</u>	<u>Observed</u>	<u>RR</u>	<u>Excess</u>
< 0.005	4,901	1.00	1
0.005 - 0.1	4,184	1.01	77
0.1 - 0.2	883	1.11	68
0.2 - 0.5	1,044	1.20	169
0.5 - 1	626	1.45	188
1-2	392	1.94	174
2+	116	2.42	80

*757 excess cancers*

Preliminary data – not for distribution


# Solid Cancers



Preliminary data – not for distribution


# Solid Cancer Incidence

## Dose Response




# Solid Cancer Temporal Patterns

Excess Relative Risk



Excess Absolute Rate




Attained Age

Preliminary data – not for distribution


# Solid Cancer Risks by Gender

*(for person age 60 exposed at age 30)*

**ERR per Sv**



**EAR per 10,000 PY Sv**




Preliminary data – not for distribution

# Site-Specific Risks

Preliminary data – not for distribution

# Site-Specific Risk Estimates

*(for person age 60 exposed at age 30)*




Preliminary data – not for distribution



# Gender Effects


*(for person age 60 exposed at age 30)*



Preliminary data – not for distribution

# Stomach Cancer

142 excess cases among 3,354



$$\text{ERR/Sv} = 0.46^*$$


$$\text{EAR}/10^4 \text{ PYSv} = 7.7^*$$

\*for person age 60 exposed at age 30

Preliminary data – not for distribution

# Breast Cancer

140 excess cases among 771



$$\text{ERR}/\text{Sv} = 0.46^*$$



$$\text{EAR}/10^4 \text{ PYSv} = 7.7^*$$

\*for person age 60 exposed at age 30

Preliminary data – not for distribution

# Lung Cancer

107 excess cases



$$\text{ERR/Sv}^* = 1.07$$

$$\text{EAR}/10^4 \text{ PY Sv}^* = 4.3$$

\*for person age 60 exposed at age 30

Preliminary data – not for distribution

# **Site-Specific Incidence: Special Pathology Studies**

- **Additional case-finding**
- **Benign tumors**
- **Review of pathology slides and records**
- **Detailed histologic diagnosis**
- **Allow for additional analyses**

# Salivary Gland Tumors, 1950-87

Malignant (n=41)		Benign (n=94)	
ERR <sub>1Sv</sub>	EAR/10 <sup>4</sup> PY Sv	ERR <sub>1Sv</sub>	EAR/10 <sup>4</sup> PYSv
3.5 (1.5-7.5)	3.7 (2.0-6.0)	0.7 (0.1-1.7)	1.9 (0.27-4.2)

*Includes NIC, 90% CI; Land et al, 1996*

Preliminary data – not for distribution

# Salivary Gland Tumors, 1950-87

	Malignant	Benign
No.	41	94
ERR <sub>1Sv</sub>	3.5 (1.5-7.5)	0.7 (0.1-1.7)
EAR/10 <sup>4</sup> PY	3.7 (2.0-6.0)	1.9 (0.27-4.2)

*Includes NIC, 90% CI; Land et al, 1996*

Preliminary data – not for distribution

# Salivary Gland Tumors, 1950-87

Level of risk differs by cell type

---

Mucoepidermoid carcinoma  $ERR_{sv}=8.3$

Other malignant  $ERR_{sv}= 1.4$

Warthin's tumor  $ERR_{sv}= 3.1$

Other benign  $ERR_{sv}=0.3$

*Includes NIC, 90% CI; Land et al, 1996*

Preliminary data – not for distribution



# Skin Tumors, 1958-89

Histology	ERR <sub>Sv</sub>	90% CI
Melanoma	2.1	<0.1; 12
Nonmelanoma	0.6	0.23; 1.3
<i>Basal cell</i>	1.8	0.83; 3.3
<i>Squamous cell</i>	<-0.1	<-0.1; 0.1
<i>Other epithelial</i>	1.4	0.02; 5.8
<i>Non-epithelial &amp; NOS</i>	0.5	<-0.1; 6.7
Bowen's tumor	0.9	-0.4; 3.1

*Ron et al, 1998*

Preliminary data – not for distribution

# Basal Cell Carcinoma, 1958-89

Age at Exposure	No. Cancers	ERR <sub>Sv</sub> (90%CI)
0-9	3	21 (4.1 ; 73)
10-19	8	6.7 (2.1 ; 17)
20-39	28	1.7 (0.5 ; 3.8)
40+	41	0.7 (-0.05 ; 2.2)

*Heterogeneity  $P=0.03$ ; Trend  $P < 0.001$*

*Ron et al, 1998*

Preliminary data – not for distribution

# Basal Cell Carcinoma, 1958-89

UV exposure*	Cancers	ERR <sub>Sv</sub> (90%CI)
High	37	0.4 (< -0.1 ; 2.1)
Low	43	4.7 (1.2 ; 13)

*Heterogeneity  $P < 0.02$*

**\*Estimates for a person exposed to the bombings at age 30**  
**High = face and hands; Low = rest of body**

Preliminary data – not for distribution

# Skin Tumors

- Possible non-linear dose response
- Risk only for basal cell carcinoma
- Increased risk during childhood
- No interaction with UV
- Almost no melanomas

# Nervous System Tumors, 1958-95

Histology	Cases	ERR <sub>Sv</sub>	90% CI
All CNS	228	1.2	0.7; 1.9
<i>Glioma</i>	43	0.56	-0.1; 1.8
<i>Meningioma</i>	88	0.64	0.03; 1.6
<i>Schwannoma</i>	55	4.5	2.0; 7.3
<i>Other</i>	42	0.51	-0.2-1.9
Benign Pituitary	35	0.98	-0.1; 3.1

*Preston et al, 2002*

Preliminary data – not for distribution

# Nervous System Tumors, 1958-95


	Schwannoma	Other
<hr/>		
Gender		
Male	8.0*	1.4
Female	2.4	0.11
	$P = 0.12$	$P = 0.05$
Age at Exposure		
<20	6.0	1.2
20-40	2.7	0.3
40+	3.3	0.1
	$P\text{-trend} > 0.5$	$P\text{-trend} = 0.06$
* $ERR_{Sv}$		

*Preston et al, 2002*

Preliminary data – not for distribution

# Nervous System Tumors, 1958-95

## Dose Response



Preliminary data – not for distribution

# CNS Tumors

- First time excess risk of all neural tumors combined seen in A-bomb survivors
- Risk continued throughout follow-up
- Highest risk seen for Schwannomas
- Age at exposure effect mostly for meningiomas
- Patterns of risk similar to other studies

Preliminary data – not for distribution



# Thyroid Tumors, 1958-94


<b>Tumors</b>	<b>Malignant</b>	<b>Benign</b>
<b>Non-autopsy</b>	<b>264 (84%)*</b>	<b>84 (82%)</b>
<b>Autopsy</b>	<b>133 (62%)</b>	<b>47 (68%)</b>
<b>Total</b>	<b>397 (77%)</b>	<b>131 (77%)</b>

*\* (%) of cases in women*

Preliminary data – not for distribution

# Thyroid Cancer Dose Response

*(for person age 0-9 at exposure)*



Preliminary data – not for distribution


# Thyroid Cancer, 1958-94

Age at exposure	Non-autopsy cases	All cases
0 – 9	6.3 (3.6; 10.2)*	6.6 (3.4; 12.4)
10 – 19	2.3 (1.1; 3.9)	2.1 (0.9; 4.0)
20 – 39	0.4 (-0.1; 3.9)	0.5 (0.0; 1.4)
40+	< 0 (-0.2; 0.6)	0.3 (-0.1; 1.0)

*\*Excess Relative Risks/Sv; 90% confidence interval*


Preliminary data – not for distribution

# Thyroid Cancer Incidence



Age at Exposure

10 — 30 — 50 —



$ERR/Sv^* = 0.99$

$EAR/10^4 PY Sv^* = 1.2$

71 excess cases

*\*for person age 60 exposed at age 30*

Preliminary data – not for distribution

# Benign Thyroid Tumors

Age at Exposure	Benign Tumors	ERR/Sv
0-9	24	2.5
10-19	29	<0
20-39	28	<0
40+	50	1.1

Preliminary data – not for distribution

# Thyroid Tumors

- Strong dose-response relation for thyroid cancers and benign tumors
- Risks decreased with increasing age at exposure
- Little evidence that high risks following childhood exposures decrease with time
- Patterns generally similar to those seen in other studies

# NEW FINDINGS

- Large excess relative risk for endometrial cancer among women exposed to the bomb before age 20
- Radiation effect observed for male breast cancer

# Summary (1)

- **Solid cancer dose response continues to be linear**
- **Lifetime solid cancer excess estimated as about 10 times that for leukemia**
- **Excess risk continues throughout life**



# Summary (2)

- Age-time patterns don't differ substantially for most individual sites
- With more detailed analyses, age at exposure and attained age differences difficult to distinguish

# Future

- Continued follow-up is necessary to understand risk patterns for persons less than age 20 years ATB
- Additional site-specific incidence studies will provide needed information on the radiation-sensitivity of specific histologies